Lisaftoclax

Near Add Your Location

Not yet accepting

Lisaftoclax

A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4).
Learn more
  • BCL-2 Inhibitor
  • Placebo
  • Randomization
  • Phase 3

Accepting patients

APG-2575 Plus Azacitidine

A Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS
Learn more
  • Antimetabolites
  • BCL-2 Inhibitor
  • Phase 1/2